Gamma interferon is not essential in host defense against disseminated candidiasis in mice

Infection and Immunity

Volumn 65, Issue 5, 1997, Pages 1748-1753

  Qian, Qinfang ^a   Cutler, Jim E ^a  

^a MONTANA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANDIDIASIS; ENZYME LINKED IMMUNOSORBENT ASSAY; GENOTYPE; HOSPITAL INFECTION; HOST RESISTANCE; IMMUNE RESPONSE; IMMUNOTHERAPY; MOUSE; NONHUMAN; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; STATISTICAL ANALYSIS; SUPPRESSOR CELL; TISSUE INJURY; YEAST;

EID: 0030939052     PISSN: 00199567     EISSN: None     Source Type: Journal    
DOI: 10.1128/iai.65.5.1748-1753.1997     Document Type: Article

References (57)

1. Amiri, P., M. Haak-Frendscho, K. Robbins, J. H. McKerrow, T. Stewart, and P. Jardieu. 1994. Anti-immunoglobulin E treatment decreases worm burden and egg production in Schistosoma mansoni-infected normal and interferon gamma knockout mice. J. Exp. Med. 180:43-51.
2. Baghian, A., and K. W. Lee. 1989. Systemic candidosis in beige mice. J. Med. Vet. Mycol. 27:51-55.
3. Balish, E., J. Jensen, T. Warner, J. Brekke, and B. Leonard. 1993. Mucosal and disseminated candidiasis in gnotobiotic SCID mice. J. Med. Vet. Mycol. 31:143-154.
4. + lymphocytes. J. Immunol. 154:5273-5281.
5. Bistoni, F., A. Vecchiarelli, E. Cenci, P. Puccetti, P. Marconi, and A. Cas- sone. 1986. Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect. Immun. 51:668-674.
6. Blasi, E., S. Farinelli, L. Varesio, and F. Bistoni. 1990. Augmentation of GG2EE macrophage cell line-mediated anti-Candida activity by gamma interferon. tumor necrosis factor, and interleukin-1. Infect. Immun. 58:1073-1077.
7. Brawner, D. L., and J. E. Cutler. 1989. Oral Candida albicans isolates from nonhospitalized normal carriers, immunocompetent hospitalized patients, and immunocompromised patients with or without acquired immunodeficiency syndrome. J. Clin. Microbiol. 27:1335-1341.
8. Cenci, E., L. Romani, A. Vecchiarelli, P. Puccetti, and F. Bistoni. 1990. T cell subsets and IFN-gamma production in resistance to systemic candidosis in immunized mice. J. Immunol. 144:4333-4339.
9. Cole, G. T., K. R. Seshan, K. T. Lynn, and M. Franco. 1993. Gastrointestinal candidiasis: histopathology of Candida-host interactions in a murine model. Mycol. Res. 97:385-408.
10. Crawford, R. M., D. S. Finbloom, J. Ohara, W. E. Paul, and M. S. Meltzer. 1987. B cell stimulatory factor-1 (interleukin 4) activates macrophages for increased tumoricidal activity and expression of la antigens. J. Immunol. 139:135-141.
11. Crawford, R. M., D. A. Leiby, S. J. Green, C. A. Nacy, A. H. Fortier, and M. S. Meltzer. 1994. Macrophage activation: a riddle of immunological resistance. Immunol. Ser. 60:29-46.
12. Cutler, J. E. 1976. Acute systemic candidiasis in normal and congenitally thymic-deficient (nude) mice, J. Reticuloendothel. Soc. 19:121-124.
13. Cutler, J. E., D. L. Brawner, K. C. Hazen, and M. A. Jutila. 1990. Characteristics of Candida albicans adherence to mouse tissue. Infect. Immun. 58:1902-1908.
14. Dalton, D. K., S. Pitts-Meek, S. Keshav, I. S. Figari, A. Bradley, and T. A. Stewart. 1993. Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. Science 259:1739-1745.
15. Denning, D. W. 1991. Epidemiology and pathogenesis of systemic fungal infections in the immunocompromised host. J. Antimicrob. Chemother. 28(Suppl. B):1-16.
16. Diamond, R. D., C. A. Lyman, and D. R. Wysong. 1991. Disparate effects of interferon-gamma and tumor necrosis factor-alpha on early neutrophil respiratory burst and fungicidal responses to Candida albicans hyphae in vitro. J. Clin. Invest. 87:711-720.
17. Economou, J. S., W. H. McBride, R. Essner, K. Rhoades, S. Golub, E. C. Holmes, and D. L. Morton. 1989. Tumor necrosis factor production by IL-2-activated macrophages in vitro and in vivo, immunology 67:514-519.
18. Fabian, I., Y. Kletter, S. Mor, C. Geller-Bernstein, M. Ben-Yaakov, B. Volovitz, and D. W. Golde. 1992. Activation of human eosinophil and neutrophil functions by haematopoietic growth factors: comparisons of IL-1, IL-3, TL-5 and GM-CSF. Br. J. Haematol. 80:137-143.
19. Flynn, J. L., J. Chan, K. J. Triebold, D. K. Dalton, T. A. Stewart, and B. R. Bloom. 1993. An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection. J. Exp. Med. 178:2249-2254.
20. Garner, R. E., U. Kuruganti, C. W. Czarniecki, H. H. Chiu, and J. E. Domer. 1989. In vivo immune responses to Candida albicans modified by treatment with recombinant murine gamma interferon. Infect. Immun. 57:1800-1808.
21. Gazzinelli, R. T., I. Eltoum, T. A. Wynn, and A. Sher. 1993. Acute cerebral toxoplasmosis is induced by in vivo neutralization of TNF-α and correlates with the down-regulated expression of inducible nitric oxide synthase and other markers of macrophage activation. J. Immunol. 151:3672-3681.
22. T gene. Antimicrob. Agents Chemother. 39:422-426.
23. Han, Y., and J. E. Cutler. 1995. Antibody response that protects against disseminated candidiasis. Infect. Immun. 63:2714-2719.
24. Hashimoto, T. 1991. In vitro study of contact-mediated killing of Candida albicans hyphae by activated murine peritoneal macrophages in a serum-free medium. Infect. Immun. 59:3555-3561.
25. Hazen, K. C., D. L. Brawner, M. H. Riesselman, M. A. Jutila, and J. E. Cutler. 1991. Differential adherence between hydrophobic and hydrophilic yeast cells of Candida albicans. Infect. Immun. 59:907-912.
26. Jarvis, W. R., and W. J. Martone. 1992. Predominant pathogens in hospital infections. J. Antimicrob. Chemother. 29:19-24.
27. Jensen, J., and E. Balish. 1993. Enhancement of susceptibility of CB-17 mice to systemic candidiasis by poly(I · C)-induced interferon. Infect. Immun. 61:3530-3532.
28. Jensen, J., T. Warner, and E. Balish. 1994. The role of phagocytic cells in resistance to disseminated candidiasis in granulocytopenic mice. J. Infect. Dis. 170:900-905.
29. Kullberg, B.-J., J. W. Van't Wout, C. Hoogstraten, and R. van Furth. 1993. Recombinant interferon-gamma enhances resistance to acute disseminated Candida albicans infection in mice. J. Infect. Dis. 168:436-443.
30. Lee, K. W., and E. Balish. 1981. Systemic candidosis in germfree, floradefined and conventional nude and thymus-bearing mice. J. Reticuloendothel. Soc. 29:71-77.
31. Li, R.-K., and J. E. Cutler. 1993. Chemical definition of an epitope/adhesin molecule on Candida albicans. J. Biol. Chem. 268:18293-18299.
32. Li, R. K., and J. E. Cutler. 1991. A cell surface/plasma membrane antigen of Candida albicans. J. Gen. Microbiol. 137:455-464.
33. Maksymiuk, A. W., S. Thongprasert, R. Hopfer, M. Luna, V. Fainstein, and G. P. Bodey. 1984. Systemic candidiasis in cancer patients. Am. J. Med. 77:20-27.
34. Marodi, L., S. Schreiber, D. C. Anderson, R. P. MacDermott, H. M. Korchak, and R. B. Johnston. 1993. Enhancement of macrophage candidacidal activity by interferon-gamma. Increased phagocytosis, killing, and calcium signal mediated by a decreased number of mannose receptors. J. Clin. Invest. 91:2596-2601.
35. Marquis, G., S. Garzon, S. Montplaisir, H. Strykowski, and N. Benhamou. 1991. Histochemical and immunochemical study of the fate of Candida albicans inside human neutrophil phagolysosomes. J. Leukocyte Biol. 50:587-599.
36. Matthews, R., S. Hodgetts, and J. Burnie. 1995. Preliminary assessment of a human recombinant antibody fragment to hsp90 in murine invasive candidiasis. J. Infect. Dis. 171:1668-1671.
37. Mazzolla, R., R. Barluzzi, L. Romani, P. Mosci, and F. Bistoni. 1991. Anti-Candida resistance in the mouse brain and effect of intracerebral administration of interleukin 1. J. Gen. Microbiol. 137:1799-1804.
38. Mourad, S., and L. Friedman. 1968. Passive immunization of mice against Candida albicans. Sabouraudia 6:103-105.
39. Numerof, R. P., F. R. Aronson, and J. W. Mier. 1988. IL-2 stimulates the production of IL-1α and IL-1β by human peripheral blood mononuclear cells. J. Immunol. 141:4250-4257.
40. Phillips, W. A., M. Croatto, and J. A. Hamilton. 1990. Priming the macrophage respiratory burst with IL-4: enhancement with TNF-α but inhibition by IFN-gamma. Immunology 70:498-503.
41. Pope, L. M., G. T. Cole, M. N. Guentzel, and L. J. Berry. 1979. Systemic and gastrointestinal candidiasis of infant mice after intragastric challenge. Infect. Immun. 25:702-707.
42. Qian, Q., M. A. Jutila, N. van Rooijen, and J. E. Cutler. 1994. Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. J. Immunol. 152:5000-5008.
43. Qian, Q., and J. E. Cutler. Unpublished data.
44. Raymond, J. R. 1988. Amphotericin B nephrotoxicity. Am. Fam. Physician 38:199-203.
45. Rhodes, J., J. Ivani, and P. Cozens. 1986. Antigen presentation by human monocytes: effects of modifying major histocompatibility complex class II antigen expression and interleukin 1 production by using recombinant interferons and corticosteroids. Eur. J. Immunol. 16:370-375.
46. + subset expression in murine candidiasis. Infect. Immun. 60:4950-4952.
47. Romani, L., A. Mencacci, E. Cenci, R. Spaccapelo, P. Mosci, P. Puccetti, and F. Bistoni. 1993. CD4+ subset expression in murine candidiasis. Th responses correlate directly with genetically determined susceptibility or vaccine-induced resistance. J. Immunol. 150:925-931.
48. Sieck, T. G., M. A. Moors, H. R. Buckley, and K. J. Blank. 1993. Protection against murine disseminated candidiasis mediated by a Candida albicans-specific T-cell line. Infect. Immun. 61:3540-3543.
49. Smith, P. D., C. L. Lamerson, S. M. Banks, S. S. Saini, L. M. Wahl, R. A. Calderone, and S. M. Wahl. 1990. Granulocyte-macrophage colony-stimulating factor augments human monocyte fungicidal activity for Candida albicans. J. Infect. Dis. 161:999-1005.
50. Stevenhagen, A., and R. van Furth. 1993. Interferon-gamma activates the oxidative killing of Candida albicans by human granulocytes. Clin. Exp. Immunol. 91:170-175.
51. Stevens, D. A., F. C. Odds, and S. Scherer. 1990. Application of DNA typing methods to Candida albicans epidemiology and correlations with phenotype. Rev. Infect. Dis. 12:258-266.
52. Tavares, D., P. Ferreira, M. Vilanova, A. Videira, and M. Arala-Chaves. 1995. Immunoprotection against systemic candidiasis in mice. Int. Immunol. 7:785-796.
53. Trinchieri, G., and B. Perussia. 1985. Immune interferon: a pleiotropic lymphokine with multiple effects. Immunol. Today 6:131-133.
54. Van't Wout, J. W., R. Poel, and R. van Furth. 1992. The role of BCG/PPD-activated macrophages in resistance against systemic candidiasis in mice. Scand. J. Immunol. 36:713-719.
55. Verdeguer, A., J. M. Fernandez, C. Esquembre, J. Ferris, J. E. Ruiz, and V. Castel. 1990. Hepatosplenic candidiasis in children with acute leukemia. Cancer 65:874-877.
56. Wenzel, R. P. 1995. Nosocomial candidemia: risk factors and attributable mortality. Clin. Infect. Dis. 20:1531-1534.
57. Worthington, M., and H. F. Hasenclever. 1972. Effect of an interferon stimulator, polyinosinic:polycytidylic acid, on experimental fungus infections. Infect. Immun. 5:199-202.